Global Point-of-Care Diagnostics Market Outlook 2020
It is widely accepted that disease prevention and risk-reduction strategies have the potential to lower disease burden as well as improve the overall health of individuals. POCT technology offers such potential for diagnosis and treatment of patients, as it facilitates rapid availability of test results and hence, earlier clinical decvision making and intervention.
Amidst of rising disease incidence, reduced budgets, growing focus towards personalization of care and ever-increasing integration of technology into healthcare, the global POCT market is expected to grow to almost US$ 30 Billion by 2020. According to “Global Point-of-Care Diagnostics Market Outlook 2020”, the global POCT industry is at a very crucial stage with POCT expanding itself into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics, as the focus shifts from curative to preventive care with enhanced patient involvement.
Currently, the United States accounts for almost 45% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings is expected to result in enhanced uptake of POCT in emerging nations. Countries such as Japan, China, India, Brazil and Mexico are expected to evolve as hot spots for development of POCT technology in the future.
The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market.
The report then moves on to the global POCT industry, its current market size and future forecasts. Markets for major application segments such as glucose testing, blood chemistry etc have also been discussed. Trends such as advanced microfluidics, lab-on-a-chip assays as well as portable technologies have been elaborated. At the end, major players of the industry have been highlighted and thorough profiling has been carried out to present POCT product portfolios, business segmentations, strengths and weakness, and recent developments of every player.
Amidst of rising disease incidence, reduced budgets, growing focus towards personalization of care and ever-increasing integration of technology into healthcare, the global POCT market is expected to grow to almost US$ 30 Billion by 2020. According to “Global Point-of-Care Diagnostics Market Outlook 2020”, the global POCT industry is at a very crucial stage with POCT expanding itself into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics, as the focus shifts from curative to preventive care with enhanced patient involvement.
Currently, the United States accounts for almost 45% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings is expected to result in enhanced uptake of POCT in emerging nations. Countries such as Japan, China, India, Brazil and Mexico are expected to evolve as hot spots for development of POCT technology in the future.
The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market.
The report then moves on to the global POCT industry, its current market size and future forecasts. Markets for major application segments such as glucose testing, blood chemistry etc have also been discussed. Trends such as advanced microfluidics, lab-on-a-chip assays as well as portable technologies have been elaborated. At the end, major players of the industry have been highlighted and thorough profiling has been carried out to present POCT product portfolios, business segmentations, strengths and weakness, and recent developments of every player.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. IN VITRO DIAGNOSTIC MARKET OVERVIEW
3.1 Introduction
3.2 What is In Vitro Diagnostics?
3.3 Market Size and Growth
4. POINT-OF-CARE DIAGNOSTICS MARKET OUTLOOK 2020
5. MARKET SEGMENTATION
5.1 By Application
5.2 By Geography
6. MARKET DRIVERS AND CHALLENGES
6.1 Drivers
6.2 Challenges
7. INDUSTRY TRENDS AND DEVELOPMENTS
7.1 Portable Ultrasound Providing Care on Site
7.2 Microfluidics Technology Crowding the POCT Industry
8. COMPETITIVE LANDSCAPE
8.1 Market Share of Major Players
8.2 Key Players
8.2.1 Roche Holding Ltd.
8.2.2 Abbott Laboratories
8.2.3 Johnson and Johnson
8.2.4 Alere
8.2.5 Medtronic
8.2.6 Bayer HealthCare
8.2.7 Siemens HealthCare
8.2.8 Beckman Coulter
8.2.9 Bio-Rad
8.2.10 Becton Dickinson
9. FUTURE OUTLOOK/MARKET OPPORTUNITIES
2. RESEARCH METHODOLOGY
3. IN VITRO DIAGNOSTIC MARKET OVERVIEW
3.1 Introduction
3.2 What is In Vitro Diagnostics?
3.3 Market Size and Growth
4. POINT-OF-CARE DIAGNOSTICS MARKET OUTLOOK 2020
5. MARKET SEGMENTATION
5.1 By Application
5.2 By Geography
6. MARKET DRIVERS AND CHALLENGES
6.1 Drivers
6.2 Challenges
7. INDUSTRY TRENDS AND DEVELOPMENTS
7.1 Portable Ultrasound Providing Care on Site
7.2 Microfluidics Technology Crowding the POCT Industry
8. COMPETITIVE LANDSCAPE
8.1 Market Share of Major Players
8.2 Key Players
8.2.1 Roche Holding Ltd.
8.2.2 Abbott Laboratories
8.2.3 Johnson and Johnson
8.2.4 Alere
8.2.5 Medtronic
8.2.6 Bayer HealthCare
8.2.7 Siemens HealthCare
8.2.8 Beckman Coulter
8.2.9 Bio-Rad
8.2.10 Becton Dickinson
9. FUTURE OUTLOOK/MARKET OPPORTUNITIES
LIST OF FIGURES:
Figure 3-1: Global - Diabetes Incidence (Million), 2014 & 2035
Figure 3-2: Global - In Vitro Diagnostic Market (Billion US$), 2014-2020
Figure 3-3: Global - In Vitro Diagnostic Market by Region (%), 2014
Figure 3-4: Global - In Vitro Diagnostic Market by Region (%), 2020
Figure 3-5: Global - In Vitro Diagnostic Market by Players (%), 2014
Figure 4-1: Global - Share of POCT in the IVD Market (%), 2014 & 2020
Figure 4-2: Global - Point of Care Testing Market (Billion US$), 2014-2020
Figure 5-1: Global - Point of Care Testing Market by Application (%), 2014
Figure 5-2: Global - Point of Care Testing Market by Application (%), 2020
Figure 5-3: Global - Point of Care Testing Market by Players (%), 2014
Figure 8-1: Global - Point-of-Care Testing Market by Players (%), 2014
Figure 8-2: Roche Holdings Ltd - Revenue by Business Segment (%), 2014
Figure 8-3: Abbott Laboratories - Revenue by Business Segment (%), 2014
Figure 8-4: Abbott Laboratories - Revenue by Region (%), 2014
Figure 8-5: Johnson & Johnson - Revenue by Business Segment (%), 2014
Figure 8-6: Johnson & Johnson - Medical Devices and Dx Revenue by Segment (%), 2014
Figure 8-7: Johnson & Johnson - Revenue by Region (%), 2014
Figure 8-8: Johnson & Johnson - Medical Devices and Dx Revenue by Region (%), 2014
Figure 8-9: Alere Inc. - Revenue by Business Segment (%), 2013
Figure 8-10: Alere Inc. - Professional Diagnostic Division Revenue by Segment (%), 2013
Figure 8-11: Medtronic Inc. - Revenue by Business Segment (%), 2014
Figure 8-12: Medtronic Inc. - Revenue by Region (%), 2014
Figure 8-13: Bayer HealthCare - Revenue by Business Segment (%), 2014
Figure 8-14: Bayer HealthCare - Revenue by Business Region (%), 2014
Figure 8-15: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2014
Figure 8-16: Siemens HealthCare - Revenue by Region (%), 2014
Figure 8-17: Siemens HealthCare - Revenue by Business Segment (%), 2014
Figure 8-18: Bio-Rad - Revenue by Segment (%), 2014
Figure 8-19: Bio-Rad - Revenue by Region (%), 2014
Figure 8-20: Becton Dickinson - Revenue by Business Segment (%), 2014
Figure 8-21: Becton Dickinson - Revenue by Region (%), 2014
Figure 3-1: Global - Diabetes Incidence (Million), 2014 & 2035
Figure 3-2: Global - In Vitro Diagnostic Market (Billion US$), 2014-2020
Figure 3-3: Global - In Vitro Diagnostic Market by Region (%), 2014
Figure 3-4: Global - In Vitro Diagnostic Market by Region (%), 2020
Figure 3-5: Global - In Vitro Diagnostic Market by Players (%), 2014
Figure 4-1: Global - Share of POCT in the IVD Market (%), 2014 & 2020
Figure 4-2: Global - Point of Care Testing Market (Billion US$), 2014-2020
Figure 5-1: Global - Point of Care Testing Market by Application (%), 2014
Figure 5-2: Global - Point of Care Testing Market by Application (%), 2020
Figure 5-3: Global - Point of Care Testing Market by Players (%), 2014
Figure 8-1: Global - Point-of-Care Testing Market by Players (%), 2014
Figure 8-2: Roche Holdings Ltd - Revenue by Business Segment (%), 2014
Figure 8-3: Abbott Laboratories - Revenue by Business Segment (%), 2014
Figure 8-4: Abbott Laboratories - Revenue by Region (%), 2014
Figure 8-5: Johnson & Johnson - Revenue by Business Segment (%), 2014
Figure 8-6: Johnson & Johnson - Medical Devices and Dx Revenue by Segment (%), 2014
Figure 8-7: Johnson & Johnson - Revenue by Region (%), 2014
Figure 8-8: Johnson & Johnson - Medical Devices and Dx Revenue by Region (%), 2014
Figure 8-9: Alere Inc. - Revenue by Business Segment (%), 2013
Figure 8-10: Alere Inc. - Professional Diagnostic Division Revenue by Segment (%), 2013
Figure 8-11: Medtronic Inc. - Revenue by Business Segment (%), 2014
Figure 8-12: Medtronic Inc. - Revenue by Region (%), 2014
Figure 8-13: Bayer HealthCare - Revenue by Business Segment (%), 2014
Figure 8-14: Bayer HealthCare - Revenue by Business Region (%), 2014
Figure 8-15: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2014
Figure 8-16: Siemens HealthCare - Revenue by Region (%), 2014
Figure 8-17: Siemens HealthCare - Revenue by Business Segment (%), 2014
Figure 8-18: Bio-Rad - Revenue by Segment (%), 2014
Figure 8-19: Bio-Rad - Revenue by Region (%), 2014
Figure 8-20: Becton Dickinson - Revenue by Business Segment (%), 2014
Figure 8-21: Becton Dickinson - Revenue by Region (%), 2014
LIST OF TABLES:
Table 8-1: Roche Holdings Ltd - POCT Product Portfolio
Table 8-2: Roche Holdings Ltd - Key POCT Product Launches for 2015
Table 8-3: Roche Holdings Ltd - Key Financials (Million CHF), 2012-2014
Table 8-4: Roche Holdings Ltd - Strengths and Weaknesses
Table 8-5: Abbott Laboratories - POCT Product Portfolio
Table 8-6: Abbott Laboratories - Key Financials (Million US$), 2012-2014
Table 8-7: Abbott Laboratories - Strengths and Weaknesses
Table 8-8: Johnson & Johnson - POCT Product Portfolio
Table 8-9: Johnson & Johnson - Key Financials (Million US$), 2012-2014
Table 8-10: Johnson & Johnson - Strengths and Weaknesses
Table 8-11: Alere Inc. - POCT Product Portfolio
Table 8-12: Alere Inc. - Key Financials (Million US$), 2011-2013
Table 8-13: Alere Inc. - Strengths and Weaknesses
Table 8-14: Medtronic Inc. - POCT Product Portfolio
Table 8-15: Medtronic Inc. - Key Financials (Million US$), 2012-2014
Table 8-16: Medtronic Inc. - Strengths and Weaknesses
Table 8-17: Bayer HealthCare - POCT Product Portfolio
Table 8-18: Bayer HealthCare - Key Financials (Million €), 2012-2014
Table 8-19: Bayer HealthCare - Strengths and Weaknesses
Table 8-20: Siemens Healthcare - POCT Product Portfolio
Table 8-21: Siemens Healthcare - Key Financials (Million €), 2012-2014
Table 8-22: Siemens Healthcare - Strength and Weaknesses
Table 8-23: Beckman Coulter - POCT Product Portfolio
Table 8-24: Beckman Coulter - Strengths and Weaknesses
Table 8-25: Bio-Rad - POCT Product Portfolio
Table 8-26: Bio-Rad - Key Financials (Million US$) 2012-2014
Table 8-27: Bio-Rad - Strengths and Weaknesses
Table 8-28: Becton Dickinson - POCT Product Portfolio
Table 8-29: Becton Dickinson - Key Financials (Million US$), 2012-2014
Table 8-30: Becton Dickinson - Strengths and Weaknesses
Table 8-1: Roche Holdings Ltd - POCT Product Portfolio
Table 8-2: Roche Holdings Ltd - Key POCT Product Launches for 2015
Table 8-3: Roche Holdings Ltd - Key Financials (Million CHF), 2012-2014
Table 8-4: Roche Holdings Ltd - Strengths and Weaknesses
Table 8-5: Abbott Laboratories - POCT Product Portfolio
Table 8-6: Abbott Laboratories - Key Financials (Million US$), 2012-2014
Table 8-7: Abbott Laboratories - Strengths and Weaknesses
Table 8-8: Johnson & Johnson - POCT Product Portfolio
Table 8-9: Johnson & Johnson - Key Financials (Million US$), 2012-2014
Table 8-10: Johnson & Johnson - Strengths and Weaknesses
Table 8-11: Alere Inc. - POCT Product Portfolio
Table 8-12: Alere Inc. - Key Financials (Million US$), 2011-2013
Table 8-13: Alere Inc. - Strengths and Weaknesses
Table 8-14: Medtronic Inc. - POCT Product Portfolio
Table 8-15: Medtronic Inc. - Key Financials (Million US$), 2012-2014
Table 8-16: Medtronic Inc. - Strengths and Weaknesses
Table 8-17: Bayer HealthCare - POCT Product Portfolio
Table 8-18: Bayer HealthCare - Key Financials (Million €), 2012-2014
Table 8-19: Bayer HealthCare - Strengths and Weaknesses
Table 8-20: Siemens Healthcare - POCT Product Portfolio
Table 8-21: Siemens Healthcare - Key Financials (Million €), 2012-2014
Table 8-22: Siemens Healthcare - Strength and Weaknesses
Table 8-23: Beckman Coulter - POCT Product Portfolio
Table 8-24: Beckman Coulter - Strengths and Weaknesses
Table 8-25: Bio-Rad - POCT Product Portfolio
Table 8-26: Bio-Rad - Key Financials (Million US$) 2012-2014
Table 8-27: Bio-Rad - Strengths and Weaknesses
Table 8-28: Becton Dickinson - POCT Product Portfolio
Table 8-29: Becton Dickinson - Key Financials (Million US$), 2012-2014
Table 8-30: Becton Dickinson - Strengths and Weaknesses
